Juno Therapeutics, Inc. (NASDAQ:JUNO) General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $44.92, for a total value of $1,257,760.00. Following the sale, the general counsel now directly owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Juno Therapeutics, Inc. (JUNO) traded down 1.65% during trading on Thursday, hitting $44.57. The stock had a trading volume of 4,713,333 shares. The company’s market cap is $4.68 billion. The firm’s 50-day moving average price is $33.60 and its 200-day moving average price is $26.98. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $47.00.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. The company’s quarterly revenue was down 22.8% on a year-over-year basis. Analysts predict that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Juno Therapeutics, Inc. (JUNO) General Counsel Sells 28,000 Shares of Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/14/insider-selling-juno-therapeutics-inc-juno-general-counsel-sells-28000-shares-of-stock.html.

A number of hedge funds have recently bought and sold shares of the stock. Utah Retirement Systems boosted its holdings in Juno Therapeutics by 1.8% in the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 200 shares during the last quarter. State of Wisconsin Investment Board boosted its holdings in Juno Therapeutics by 1.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Amalgamated Bank boosted its holdings in Juno Therapeutics by 19.0% in the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 1,741 shares during the last quarter. Finally, Evercore Wealth Management LLC boosted its holdings in Juno Therapeutics by 6.7% in the 2nd quarter. Evercore Wealth Management LLC now owns 32,062 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 70.76% of the company’s stock.

Several analysts have issued reports on JUNO shares. Leerink Swann reissued an “outperform” rating on shares of Juno Therapeutics in a report on Monday, June 12th. Vetr raised Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target for the company in a report on Monday, August 14th. Zacks Investment Research lowered Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Morgan Stanley boosted their price target on Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, August 7th. Finally, Raymond James Financial, Inc. raised Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target for the company in a report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.88.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.